Location: Home
  • search
  • go
  • Relate News
  • 10/23/2024Guangzhou Aims to Establish Itself as a Global Biopharmaceutical Hub
  • 10/23/2024China Recovers CNY 16B in Misused BMI Funds
  • 10/22/2024Bristol Ends LaNova Partnership on Claudin18.2 ADC, Eyes Potential I-M...
  • 10/22/2024XellSmart RaisesCNY 100M+ in Series B1 Financing for iPS-Derived Cell ...
  • 10/21/2024Akeso Launches Phase 1/2 Trial for Novel Bispecific Antibody Combinati...
  • 10/21/2024BeiGene's Secures 14th Indication in China for Tislelizumab
  • 10/21/2024NMPA Issues the Pilot Plan for Staged Production of Biological Product...
  • 10/21/2024Changing Chinese Market Dynamics Hit Merck Where It Hurts (SCRIP Citel...
  • 10/18/2024AstraZeneca Submits Marketing Applications for Tremelimumab and Durval...
  • 10/18/2024NMPA Launches Pilot Reform for Staged Production of Biologicals
  • 10/18/2024Recent Executive Moves
  • 10/17/2024MSD Files NDA for WINREVAIR (sotatercept) in China
  • 10/17/2024China Initiates Data Collection for the 10th Round of the National Lev...
  • 10/17/2024Hutchmed Announces Positive Results from Phase II SAVANNAH Trial for L...
  • 10/16/2024Cytokinetics and Jixing Pharma Jointly Submit Chinese NDA for Aficamte...
  • 10/16/2024Hengrui Resubmits BLA to the USFDA for Anti-PD-1 Antibody Camrelizumab
  • 10/16/2024GSK's Submits Priority Review Application for BCMA ADC in China
  • 10/16/2024NHSA Issues the Notice on Regulating the Management of Externally-fill...
  • 10/16/2024China's New Policies On Foreign Investment In Healthcare And Biotechno...
  • 10/16/2024China Biopharma Tracker – Q3 2024 (PharmaDJ)
  • 10/15/2024AstraZeneca/Daiichi's Enhertu Approved in China as First HER2-directed...
  • 10/15/2024BrightGene's Phase 2 Trial of BGM0504 Injection Shows Significant Weig...
  • 10/15/2024Eli Lilly Invests $200M to Expand Chinese Manufacturing Facility for D...
  • 10/15/2024China Solicits Comments on Draft Compliance Guidelines for Pharmaceuti...
  • 10/15/2024Review of Online Drug Sales Growth in China 2021-2023
  • 10/11/2024Chinese Health Insurance Premium Income Up 4.5% in 2023
  • 10/11/2024Recent Executive Moves
  • 10/10/2024QuantumPharma's Subsidiary Ailux Biologics Partners with Janssen Biote...
  • 10/10/2024Eli Lilly Submits Chinese NDA for Its Anti-IL23 Antibody Mirikizumab
  • 10/10/2024Guangdong Aims to Boost Biopharma Sector to Over CNY 1 Trillion by 202...
  • Page:21/359 Total number of articles:10754: [First][<<] [19] [20] [21] [22] [23] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group